Last $0.0048 USD
Change Today 0.00 / 0.00%
Volume 10.2K
NGSX On Other Exchanges
Symbol
Exchange
Berlin
As of 5:20 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

neurogesx inc (NGSX) Snapshot

Open
$0.0070
Previous Close
$0.0048
Day High
$0.0070
Day Low
$0.0048
52 Week High
01/22/14 - $0.02
52 Week Low
12/23/13 - $0.0025
Market Cap
160.0K
Average Volume 10 Days
19.7K
EPS TTM
$-0.92
Shares Outstanding
33.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROGESX INC (NGSX)

Related News

No related news articles were found.

neurogesx inc (NGSX) Related Businessweek News

No Related Businessweek News Found

neurogesx inc (NGSX) Details

NeurogesX, Inc., a biopharmaceutical company, engages in developing and commercializing pain management therapies. The company offers Qutenza for the management of neuropathic pain associated with postherpetic neuralgia, and for the treatment of peripheral neuropathic pain in non-diabetic adults. It also develops NGX-1998, which has completed Phase 2 clinical study, is a topical liquid formulation of high concentration capsaicin to treat neuropathic pain conditions; and acetaminophen prodrugs that is in preclinical stage for use in acute pain, including traumatic pain, post-surgical pain, and fever. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California.

35 Employees
Last Reported Date: 03/28/12
Founded in 1998

neurogesx inc (NGSX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neurogesx inc (NGSX) Key Developments

NeurogesX, Inc. Terminates Employment of its Executive Officers

NeurogesX, Inc. has terminated the employment of Ronald Martell, President and Chief Executive Officer, Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer, and Stephen Peroutka, Executive Vice President and Chief Medical Officer, effective from one business day following the closing the Asset Sales, and such individuals executed releases of the company.

NeurogesX, Inc., Special/Extraordinary Shareholders Meeting, Jun 18, 2013

NeurogesX, Inc., Special/Extraordinary Shareholders Meeting, Jun 18, 2013., at 11:00 Pacific Daylight. Location: Morrison & Foerster LLP, 425 Market Street. Agenda: To consider and vote upon the sale of certain of the Company's assets to Acorda Therapeutics, Inc.; to consider and vote upon one or more adjournments of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1; and to transact such other business as may properly come before the special meeting or any adjournment or postponement.

NeurogesX, Inc. To Be Deleted From OTCBB

NeurogesX, Inc.’s common stock will be deleted from OTC Bulletin Board (OTCBB) effective May 21, 2013, on account of its failure to comply with NASD 6530. The company will be added to NBB.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NGSX:US $0.00 USD 0.00

NGSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
POZEN Inc $8.09 USD +0.20
Sunesis Pharmaceuticals Inc $7.00 USD 0.00
View Industry Companies
 

Industry Analysis

NGSX

Industry Average

Valuation NGSX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROGESX INC, please visit www.neurogesx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.